NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Zafgen, Inc. (NASDAQ:ZFGN) resulting from allegations that Zafgen may have issued materially misleading business information to the investing public.
On October 16, 2015, Zafgen announced that the FDA had ordered a “partial clinical hold” on Zafgen’s Beloranib clinical trials following the death of a patient. Zafgen also disclosed that six patients in previous and current trials reported thrombotic adverse events, including blood clots in the legs and in the lungs. On this news, shares of Zafgen fell sharply during intraday trading on October 16, 2015, damaging investors.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Zafgen investors. If you purchased shares of Zafgen prior to October 16, 2015, please visit the firm’s website at http://rosenlegal.com/cases-752.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
